Johnson & Johnson (JNJ) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Johnson & Johnson (JNJ)

270.24

+2.87 (1.07%)

as of Aug 21, 2026, 8:00:00 pm Market Open.

697 watching

Investor Insights

Aug 21, 2026, 12:00 am

This summary was created by AI, based on 10 opinions in the last 12 months.

Johnson & Johnson (JNJ) has shown some volatility recently, primarily due to performance issues in its cardio business, despite reporting a solid beat-and-raise quarter. The company has successfully addressed past legal challenges related to talcum powder, minimizing the overhang of these lawsuits. Analysts are optimistic about JNJ’s upcoming earnings report expected on July 15, anticipating positive news about its oncology drugs and orthopedic business, although caution persists due to erratic stock movements following disclosure of results. The spin-off of the orthopedics division is viewed positively as it shifts focus towards higher-margin pharmaceutical and medical device sectors. Overall, JNJ is seen as a solid investment due to its strong drug pipeline and improved balance sheet, even as the company navigates its litigation concerns.

Consensus

Buy

Valuation

Fair Value

Similar

BUY

Great company. You get the benefit of both pharmaceutical and consumer sides. Pristine balance sheet. Good dividend. Great core holding in any portfolio.

TOP PICK

Not a pure pharmaceutical company. Has a consumer part. Made a very good acquisition of Pfizer’s (PFE-N) consumer related products. Lots of cash. Going into the cosmetic surgery business. 3% yield.

HOLD

Attractive stock for a long-term investor. Has been consistently beating estimates and estimates have been rising. As volatility comes out of the market, people are going to be willing to pay for this level of quality.

TOP PICK

Have medical devices, consumer products and pharmaceuticals. Acquisition of Pfizer's consumer products division in 2006 was very good. Fantastic balance sheet. Net cash.

TOP PICK

Good company to own in this kind of a difficult market. Not only a pharmaceutical and medical devices company but also a consumers product company. Made an astute acquisition of Pfizer's (PFE-N) consumers’ products. Almost 6% dividend.

TRADE

Have medical Device business, Consumer business, great company, a lot of which is not sensitive to politics.

BUY

Very interesting, very stable.

BUY

Diversified medical supply and pharmaceutical. Hitting new highs but valuation is still among the cheapest at 15X earnings. Double-digit growth through many years. 2.6% yield. Has a little bit of upside left. Long-term hold.

BUY

Consumer products and pharmaceuticals. Has the confidence of the shareholders and has done very well. Strong balance sheet. Stable company. Well-placed for a growth environment.

BUY

Great company and has been an excellent stock. Really isn't a pharmaceutical stock. Big in medical devices. Also a large consumers product company.

TOP PICK

Recently had a huge breakout. Had not cleared the $70 for ages. People who had shorted are now scrambling to cover. You don't want to be in this event starts coming back too far.

BUY

Home healthcare products and health/beauty aids are very solid products in the US. Less enthusiastic about the medical devices business and pharmaceuticals but overall it is a tremendously strong company with a very good dividend. Has been undervalued for about 5 years.

TOP PICK

(Sneaked in a 4th Top Pick.) An absolutely unbelievable technical breakout. Had not gone past its $69-$70 level since 2005. See it heading towards the $100 level.

BUY

Medical Device manufacturing. Should be a core holding for conservative investors. They have good growth projects. 40%-50% international exposure

BUY

Stable cash flow. A solid name to own in these volatile markets.

Showing 496 to 510 of 628 entries

Most Recent Experts

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Josh Brown, CEO, Ritholtz Wealth Management

Ritholtz Wealth Management

Amy Raskin, CIO, Chevy Chase Trust

Chevy Chase Trust

Darren Sissons

Campbell Lee & Ross

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Summer Sale

Johnson & Johnson (JNJ)